Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Drug Metab Dispos. 2012 Sep;40(9):1744-56. doi: 10.1124/dmd.112.046193. Epub 2012 Jun 4.
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation. The uptake kinetics of seven organic anion-transporting polypeptide substrates was investigated over a concentration range in plated cryopreserved human hepatocytes. Active uptake clearance (CL(active, u)), bidirectional passive diffusion (P(diff)), intracellular binding, and metabolism were estimated for bosentan, pitavastatin, pravastatin, repaglinide, rosuvastatin, telmisartan, and valsartan in HU4122 donor using a mechanistic two-compartment model in Matlab. Full uptake kinetics of rosuvastatin and repaglinide were also characterized in two additional donors, whereas for the remaining drugs CL(active, u) was estimated at a single concentration. The unbound affinity constant (K(m, u)) and P(diff) values were consistent across donors, whereas V(max) was on average up to 2.8-fold greater in donor HU4122. Consistency in K(m, u) values allowed extrapolation of single concentration uptake activity data and assessment of interindividual variability in CL(active) across donors. The maximal contribution of active transport to total uptake differed among donors, for example, 85 to 96% and 68 to 87% for rosuvastatin and repaglinide, respectively; however, in all cases the active process was the major contributor. In vitro-in vivo extrapolation indicated a general underprediction of hepatic intrinsic clearance, an average empirical scaling factor of 17.1 was estimated on the basis of seven drugs investigated in three hepatocyte donors, and donor-specific differences in empirical factors are discussed. Uptake K(m, u) and CL(active, u) were on average 4.3- and 7.1-fold lower in human hepatocytes compared with our previously published rat data. A strategy for the use of rat uptake data to facilitate the experimental design in human hepatocytes is discussed.
在体内,摄取转运体的个体间变异性是明显的,但在体外的数据有限,这使得体外-体内推断复杂化。在培养的冷冻保存人肝细胞中,研究了七种有机阴离子转运蛋白底物的浓度范围内的摄取动力学。使用 Matlab 中的机械两室模型,在 HU4122 供体中估算了 bosentan、pitavastatin、pravastatin、repaglinide、rosuvastatin、telmisartan 和 valsartan 的主动摄取清除率(CL(active, u))、双向被动扩散(P(diff))、细胞内结合和代谢。在另外两个供体中也对 rosuvastatin 和 repaglinide 的完整摄取动力学进行了特征描述,而对于其余药物,在单个浓度下估算了 CL(active, u)。供体间的未结合亲和力常数(K(m, u))和 P(diff)值是一致的,而 V(max)平均高出 2.8 倍。K(m, u)值的一致性允许对单个浓度摄取活性数据进行外推,并评估供体间 CL(active)的个体间变异性。主动转运对总摄取的最大贡献在供体间有所不同,例如,rosuvastatin 和 repaglinide 分别为 85%至 96%和 68%至 87%;然而,在所有情况下,主动过程都是主要贡献者。体外-体内推断表明,肝内在清除率普遍被低估,根据在三个肝细胞供体中研究的七种药物,估计平均经验比例因子为 17.1,并且讨论了供体特异性经验因子差异。与我们之前发表的大鼠数据相比,人肝细胞中的摄取 K(m, u)和 CL(active, u)分别平均低 4.3 倍和 7.1 倍。讨论了使用大鼠摄取数据来促进人肝细胞实验设计的策略。